JP2010265302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010265302A5 JP2010265302A5 JP2010158334A JP2010158334A JP2010265302A5 JP 2010265302 A5 JP2010265302 A5 JP 2010265302A5 JP 2010158334 A JP2010158334 A JP 2010158334A JP 2010158334 A JP2010158334 A JP 2010158334A JP 2010265302 A5 JP2010265302 A5 JP 2010265302A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- composition
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 26
- 201000010099 disease Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- -1 carboalkoxy Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000003107 substituted aryl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 108091000080 Phosphotransferase Proteins 0.000 claims 6
- 102000020233 phosphotransferase Human genes 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004953 trihalomethyl group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 2
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- ZQHJAAMMKABEBS-UHFFFAOYSA-N morpholin-2-one Chemical compound O=C1CNCCO1 ZQHJAAMMKABEBS-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- USDPNUDGXLLJKG-UHFFFAOYSA-N COc(c(OC)cc1ncc2)cc1c2Oc(ncc(NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O)c1)c1Cl Chemical compound COc(c(OC)cc1ncc2)cc1c2Oc(ncc(NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O)c1)c1Cl USDPNUDGXLLJKG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50618103P | 2003-09-26 | 2003-09-26 | |
| US60/506,181 | 2003-09-26 | ||
| US53537704P | 2004-01-09 | 2004-01-09 | |
| US60/535,377 | 2004-01-09 | ||
| US57738404P | 2004-06-04 | 2004-06-04 | |
| US60/577,384 | 2004-06-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528265A Division JP4638436B2 (ja) | 2003-09-26 | 2004-09-24 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010265302A JP2010265302A (ja) | 2010-11-25 |
| JP2010265302A5 true JP2010265302A5 (https=) | 2011-08-18 |
| JP5325172B2 JP5325172B2 (ja) | 2013-10-23 |
Family
ID=34397024
Family Applications (14)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528265A Expired - Fee Related JP4638436B2 (ja) | 2003-09-26 | 2004-09-24 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010158334A Expired - Lifetime JP5325172B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010158336A Expired - Fee Related JP5185332B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010158335A Expired - Lifetime JP5185331B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010158337A Expired - Fee Related JP5325173B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010256317A Withdrawn JP2011042686A (ja) | 2003-09-26 | 2010-11-16 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2013268453A Ceased JP2014074059A (ja) | 2003-09-26 | 2013-12-26 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2013268454A Expired - Lifetime JP5694501B2 (ja) | 2003-09-26 | 2013-12-26 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2013268455A Pending JP2014055191A (ja) | 2003-09-26 | 2013-12-26 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2015087327A Withdrawn JP2015131859A (ja) | 2003-09-26 | 2015-04-22 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2017123131A Withdrawn JP2017160270A (ja) | 2003-09-26 | 2017-06-23 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2019002497A Withdrawn JP2019070015A (ja) | 2003-09-26 | 2019-01-10 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2020209919A Withdrawn JP2021050233A (ja) | 2003-09-26 | 2020-12-18 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2023201921A Pending JP2024023447A (ja) | 2003-09-26 | 2023-11-29 | ｃ－Ｍｅｔモジュレーターおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528265A Expired - Fee Related JP4638436B2 (ja) | 2003-09-26 | 2004-09-24 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
Family Applications After (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010158336A Expired - Fee Related JP5185332B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010158335A Expired - Lifetime JP5185331B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010158337A Expired - Fee Related JP5325173B2 (ja) | 2003-09-26 | 2010-07-12 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2010256317A Withdrawn JP2011042686A (ja) | 2003-09-26 | 2010-11-16 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2013268453A Ceased JP2014074059A (ja) | 2003-09-26 | 2013-12-26 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2013268454A Expired - Lifetime JP5694501B2 (ja) | 2003-09-26 | 2013-12-26 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2013268455A Pending JP2014055191A (ja) | 2003-09-26 | 2013-12-26 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2015087327A Withdrawn JP2015131859A (ja) | 2003-09-26 | 2015-04-22 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2017123131A Withdrawn JP2017160270A (ja) | 2003-09-26 | 2017-06-23 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2019002497A Withdrawn JP2019070015A (ja) | 2003-09-26 | 2019-01-10 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2020209919A Withdrawn JP2021050233A (ja) | 2003-09-26 | 2020-12-18 | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2023201921A Pending JP2024023447A (ja) | 2003-09-26 | 2023-11-29 | ｃ－Ｍｅｔモジュレーターおよびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (14) | US9174947B2 (https=) |
| EP (9) | EP2210607B1 (https=) |
| JP (14) | JP4638436B2 (https=) |
| AT (3) | ATE517091T1 (https=) |
| AU (3) | AU2004275842B2 (https=) |
| BE (1) | BE2014C055I2 (https=) |
| CA (2) | CA2744997A1 (https=) |
| CY (3) | CY1111956T1 (https=) |
| DK (4) | DK2392564T3 (https=) |
| ES (6) | ES2466818T3 (https=) |
| FR (1) | FR14C0067I2 (https=) |
| HR (4) | HRP20110707T1 (https=) |
| HU (1) | HUS1400052I1 (https=) |
| LU (1) | LU92508I2 (https=) |
| NL (1) | NL300678I2 (https=) |
| PL (3) | PL2213661T3 (https=) |
| PT (2) | PT2213661E (https=) |
| SI (4) | SI2392565T1 (https=) |
| WO (1) | WO2005030140A2 (https=) |
Families Citing this family (284)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3366959B2 (ja) | 1998-06-19 | 2003-01-14 | 三洋昭和パネルシステム株式会社 | 高さ調整自在な幅木 |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| ES2279441T3 (es) | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | Derivados de quinazolina. |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| EP1684762A4 (en) * | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| JP2007518823A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| US7531532B2 (en) * | 2004-02-27 | 2009-05-12 | Eisai R&D Management Co., Ltd. | Pyridine derivative and pyrimidine derivative |
| EP2543376A1 (en) | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| BRPI0515482A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seus usos como agentes terapêuticos |
| CN101084211A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| BRPI0516093A (pt) | 2004-10-12 | 2008-08-19 | Astrazeneca Ab | derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| EP1674466A1 (en) * | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
| US7576090B2 (en) * | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| KR101378716B1 (ko) * | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
| CA2607699A1 (en) * | 2005-06-02 | 2006-12-07 | Galaxy Biotech, Llc | Methods of treating brain tumors with antibodies |
| CA2618646A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN101198590B (zh) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2007103308A2 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| CA2649288C (en) * | 2006-04-19 | 2015-11-24 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| PL2018380T3 (pl) | 2006-05-19 | 2012-05-31 | Abbvie Bahamas Ltd | Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN |
| US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| EP2057164A1 (en) | 2006-08-07 | 2009-05-13 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| CA2661333C (en) * | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| JP2010507618A (ja) * | 2006-10-27 | 2010-03-11 | グラクソ グループ リミテッド | ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体 |
| RS54510B1 (sr) | 2006-11-22 | 2016-06-30 | Incyte Holdings Corporation | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
| WO2008079294A1 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| JP2010516680A (ja) * | 2007-01-19 | 2010-05-20 | エックスカバリー，インコーポレイテッド | キナーゼ阻害薬化合物 |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| AU2008254425A1 (en) * | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| PE20090595A1 (es) | 2007-08-15 | 2009-06-06 | Glaxo Group Ltd | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| EP3147281A1 (en) | 2008-03-17 | 2017-03-29 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| JP4667537B2 (ja) | 2008-04-10 | 2011-04-13 | 大鵬薬品工業株式会社 | アシルチオウレア化合物又はその塩、及びその用途 |
| RU2010146474A (ru) * | 2008-04-16 | 2012-05-27 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) | Производные хинолина в качестве ингибиторов axl киназ |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| TWI472529B (zh) | 2008-05-21 | 2015-02-11 | Incyte Corp | ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法 |
| US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
| CA2729909A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| EP2149565A1 (de) * | 2008-07-24 | 2010-02-03 | Bayer Schering Pharma AG | Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen |
| CN102123987A (zh) | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| AR075084A1 (es) * | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
| ES2599458T3 (es) * | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| JP5444365B2 (ja) * | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
| JP5486606B2 (ja) * | 2008-11-13 | 2014-05-07 | エクセリクシス， インク． | キノリン誘導体の調製方法 |
| US20130030172A1 (en) * | 2008-12-04 | 2013-01-31 | Exelixis, Inc. | Methods of Preparing Quinoline Derivatives |
| DE102009003975A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
| CN102510855B (zh) | 2009-07-17 | 2015-11-25 | 埃克塞里艾克西斯公司 | N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形 |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| CN102030705B (zh) * | 2009-09-30 | 2012-12-19 | 上海睿智化学研究有限公司 | 7-苄氧基-6-甲氧基-4-羟基喹啉的合成方法 |
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EA021439B1 (ru) | 2009-11-03 | 2015-06-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Хиназолиновые соединения |
| EP2521548A2 (en) * | 2009-11-27 | 2012-11-14 | Proteologics, Ltd | Quinazolin-4(3a)-one derivatives and methods of use thereof |
| DE102009056886A1 (de) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
| CN102086211B (zh) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | 作为蛋白激酶抑制剂的芳杂环化合物 |
| MX2012008898A (es) | 2010-02-03 | 2012-11-06 | Incyte Corp | Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met. |
| AU2011224203A1 (en) | 2010-03-12 | 2012-10-04 | Exelixis, Inc | Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| EP2553641A4 (en) * | 2010-03-26 | 2015-01-07 | EastNets | MOBILE PAYMENT COMPUTING SYSTEM AND METHOD |
| CN102212062B (zh) * | 2010-04-02 | 2015-04-29 | 广东东阳光药业有限公司 | 氨基酯类衍生物及其盐和使用方法 |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| CA2800998A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
| EA030435B1 (ru) * | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| US20140057908A1 (en) * | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
| MX352926B (es) * | 2010-09-27 | 2017-12-14 | Exelixis Inc | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. |
| JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| WO2012071321A1 (en) * | 2010-11-22 | 2012-05-31 | Glaxosmithkline Llc | Method of treating cancer |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
| US9604963B2 (en) | 2011-03-04 | 2017-03-28 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| MX2013012695A (es) * | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| EP2753176A4 (en) * | 2011-09-06 | 2015-10-21 | New York Blood Ct Inc | HIV INHIBITORS |
| CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| CN104395284A (zh) | 2011-10-20 | 2015-03-04 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| US8843421B2 (en) | 2011-11-01 | 2014-09-23 | Accenture Global Services Limited | Identification of entities likely to engage in a behavior |
| TW201323864A (zh) | 2011-11-08 | 2013-06-16 | Exelixis Inc | 定量癌症治療之方法 |
| IN2014CN04067A (https=) | 2011-11-08 | 2015-10-23 | Exelixis Inc | |
| AR092289A1 (es) | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| US9546179B2 (en) * | 2011-12-20 | 2017-01-17 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
| CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
| EP2620869B1 (en) | 2012-01-27 | 2017-11-01 | Optim Corporation | Portable terminal, method, and program of changing user interface |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| CN107082779A (zh) | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| WO2013180128A1 (ja) * | 2012-05-28 | 2013-12-05 | 協和発酵キリン株式会社 | 4-[4-(5員環芳香族複素環カルボニルウレイド)フェニルオキシ]キノリン誘導体 |
| CN103509024B (zh) * | 2012-06-28 | 2015-10-28 | 上海医药工业研究院 | 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用 |
| CN103626761B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 |
| CN103626762B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其应用 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
| CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
| CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103804305A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN102977014B (zh) * | 2012-11-05 | 2015-01-07 | 沈阳药科大学 | 新的喹啉类化合物及其用途 |
| CN103804381A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804290A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804298A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103804362A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
| CN103804306A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
| CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN102964308B (zh) * | 2012-11-30 | 2015-03-18 | 中国药科大学 | 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| CN103965104B (zh) * | 2013-01-29 | 2017-09-29 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
| CA2902132C (en) | 2013-02-21 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
| CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| WO2014145693A1 (en) * | 2013-03-15 | 2014-09-18 | Exelixis, Inc. | Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| CN105121404A (zh) * | 2013-03-15 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺酰胺和氨基磺酸衍生物 |
| WO2014165779A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CN104109128B (zh) * | 2013-04-19 | 2016-10-05 | 连云港润众制药有限公司 | 卡博替尼苹果酸盐及其制备方法 |
| CN104109124B (zh) * | 2013-04-19 | 2016-08-31 | 正大天晴药业集团股份有限公司 | 卡博替尼·0.5苹果酸盐的晶体 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN104370811B (zh) * | 2013-08-15 | 2019-02-12 | 广东东阳光药业有限公司 | 一种喹啉化合物的新晶型及其制备方法 |
| ES2813877T3 (es) | 2013-08-28 | 2021-03-25 | Crown Bioscience Inc Taicang | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos |
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| CN106029632B (zh) * | 2014-02-28 | 2019-06-21 | 国立大学法人东北大学 | 酰胺衍生物 |
| EP3119476A1 (en) | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| UA121655C2 (uk) | 2014-04-25 | 2020-07-10 | Екселіксіс, Інк. | Спосіб лікування аденокарциноми легень |
| WO2015177758A1 (en) | 2014-05-23 | 2015-11-26 | Mylan Laboratories Ltd | Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| EP3174854B1 (en) * | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| MX382904B (es) | 2014-08-05 | 2025-03-13 | Exelixis Inc | Combinaciones de fármacos para tratar mieloma múltiple. |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| ES2764440T3 (es) | 2014-09-19 | 2020-06-03 | New York Blood Center Inc | Fenilpirrolcarboxamidas sustituidas con actividad terapéutica en VIH |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| EP3274332B1 (en) | 2015-03-25 | 2018-12-19 | Sandoz AG | Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US20170020856A1 (en) * | 2015-06-29 | 2017-01-26 | Ontogenesis, Llc | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use |
| US20180237378A1 (en) * | 2015-08-19 | 2018-08-23 | Sandoz Ag | Asymmetric Bisamidation of Malonic Ester Derivatives |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| CN105218445B (zh) * | 2015-08-25 | 2018-05-22 | 江苏中邦制药有限公司 | 一种酪氨酸激酶抑制剂Foretinib的制备方法 |
| CN106543143B (zh) * | 2015-09-22 | 2019-03-22 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的flt3激酶抑制剂及其用途 |
| AU2016370846B2 (en) | 2015-12-18 | 2022-08-25 | Ignyta, Inc. | Combinations for the treatment of cancer |
| CN105541798B (zh) * | 2016-02-03 | 2018-01-23 | 中国人民解放军第二军医大学 | 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法 |
| CN107129465B (zh) * | 2016-02-26 | 2020-06-19 | 中国科学院上海药物研究所 | 芳基胍类化合物及其制备方法和用途 |
| US20170283426A1 (en) * | 2016-03-31 | 2017-10-05 | Merck Patent Gmbh | Compounds for the inhibition of cyclophilins and uses thereof |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CN105906568A (zh) * | 2016-04-28 | 2016-08-31 | 西安交通大学 | 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用 |
| CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
| CN106008371A (zh) * | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
| CN107556238A (zh) * | 2016-06-30 | 2018-01-09 | 深圳万乐药业有限公司 | 一种卡博替尼的合成方法 |
| WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
| US10980792B2 (en) * | 2016-09-12 | 2021-04-20 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of Cabozantinib |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| WO2018064191A1 (en) | 2016-09-27 | 2018-04-05 | The Usa Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| CN109496212B (zh) * | 2016-10-18 | 2020-08-14 | 北京康辰药业股份有限公司 | 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用 |
| EP3548007A4 (en) | 2016-12-01 | 2020-08-12 | Ignyta, Inc. | METHOD OF TREATMENT OF CANCER |
| CN106632028B (zh) * | 2016-12-22 | 2019-01-22 | 上海再启生物技术有限公司 | 一种卡博替尼的制备方法 |
| CN108329298A (zh) * | 2017-01-17 | 2018-07-27 | 南昌弘益药业有限公司 | 一类喹啉类新化合物制备方法 |
| US11198731B2 (en) | 2017-01-20 | 2021-12-14 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| WO2018151177A1 (ja) | 2017-02-15 | 2018-08-23 | 大鵬薬品工業株式会社 | 医薬組成物 |
| CN108503650B (zh) * | 2017-02-27 | 2021-02-12 | 北京赛特明强医药科技有限公司 | 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用 |
| WO2018197643A1 (en) * | 2017-04-27 | 2018-11-01 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| MA48776A (fr) | 2017-05-26 | 2020-04-08 | Exelixis Inc | Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation |
| AU2018279834B2 (en) | 2017-06-09 | 2024-05-23 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US11344543B2 (en) * | 2017-07-14 | 2022-05-31 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR102718538B1 (ko) | 2017-07-19 | 2024-10-21 | 이그니타, 인코포레이티드 | 엔트렉티닙을 포함하는 약학적 조성물 |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| TW201920104A (zh) * | 2017-08-31 | 2019-06-01 | 美商馬愈法瑪公司 | 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途 |
| JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| IL273924B2 (en) * | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN109824587A (zh) * | 2017-11-23 | 2019-05-31 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂xjf007及其中间体的制备方法 |
| CN109896997A (zh) * | 2017-12-08 | 2019-06-18 | 中国药科大学 | N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途 |
| SG11202005719UA (en) * | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| US20190262330A1 (en) * | 2017-12-21 | 2019-08-29 | Exelixis, Inc. | Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CA3088198A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CR20250117A (es) * | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| IL276411B2 (en) | 2018-02-02 | 2024-04-01 | Univ Vanderbilt | M4 muscarinic acetylcholine receptor antagonists |
| CN108264482A (zh) * | 2018-02-05 | 2018-07-10 | 南京法恩化学有限公司 | 一种卡博替尼的制备方法 |
| CA3090876C (en) | 2018-02-11 | 2022-12-06 | Beijing Scitech-Mq Pharmaceuticals Limited | Dioxinoquinoline compounds, preparation method and uses thereof |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| WO2019234761A1 (en) | 2018-06-05 | 2019-12-12 | Natco Pharma Limited | An improved process for the preparation of cabozantinib and its pharmaceutically acceptable salts thereof |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| WO2020027723A1 (en) | 2018-08-01 | 2020-02-06 | Agency For Science, Technology And Research | Bicyclic compounds as kinase modulators, methods and uses thereof |
| CN110862398B (zh) * | 2018-08-27 | 2021-04-06 | 北京赛特明强医药科技有限公司 | 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 |
| WO2020075196A1 (en) | 2018-10-11 | 2020-04-16 | Cipla Limited | Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof |
| CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| BR112021014504A2 (pt) * | 2019-01-25 | 2021-09-28 | Exelixis, Inc. | Compostos para o tratamento de transtornos dependentes de cinase |
| CN109776432B (zh) * | 2019-03-21 | 2020-07-24 | 广州六顺生物科技股份有限公司 | 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用 |
| US20220213064A1 (en) * | 2019-04-12 | 2022-07-07 | National Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
| CN111825609A (zh) * | 2019-04-22 | 2020-10-27 | 北京康辰药业股份有限公司 | 化合物晶型、其制备方法、药物组合物以及应用 |
| MX2021014773A (es) * | 2019-06-03 | 2022-01-18 | Exelixis Inc | Formas de sales cristalinas de un inhibidor de cinasas. |
| AR119069A1 (es) | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| CN110117254B (zh) * | 2019-06-20 | 2022-05-13 | 江苏君若药业有限公司 | 卡博替尼的制备方法 |
| CN112390749B (zh) * | 2019-08-19 | 2024-12-03 | 鲁南制药集团股份有限公司 | 一种卡博替尼及其中间体的合成方法 |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| CN111393363B (zh) * | 2020-04-27 | 2022-12-20 | 威海海洋生物医药产业技术研究院有限公司 | 4-苯氧基喹啉并n-磺酰脒类化合物及其制备方法和用途 |
| CN113577066B (zh) * | 2020-04-30 | 2022-12-16 | 中国科学院上海药物研究所 | 芳基胍化合物或其药学上可接受的盐的用途 |
| IT202000027678A1 (it) | 2020-11-18 | 2022-05-18 | Indena Spa | Dispersioni solide amorfe di cabozantinib-(s)-malato e processi per la loro preparazione |
| CA3202761A1 (en) | 2020-11-25 | 2022-06-02 | Nanocopoeia, Llc | Amorphous cabozantinib particles and uses thereof |
| EP4263535A1 (en) * | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| CA3213086A1 (en) * | 2021-03-24 | 2022-09-29 | Ramakrishna Parameshwar Bhat | Process for preparation of cabozantinib |
| AU2022379973A1 (en) | 2021-11-08 | 2024-06-27 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2023098853A1 (zh) * | 2021-12-03 | 2023-06-08 | 湖南湘源美东医药科技有限公司 | 卡博替尼共晶及制备方法以及作为药物或在药物制剂中的应用 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| EP4486725A1 (en) | 2022-03-01 | 2025-01-08 | Synthon B.V. | Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof |
| WO2023222946A1 (en) | 2022-05-18 | 2023-11-23 | Fermion Oy | Process for the preparation of cabozantinib |
| CN119255825A (zh) | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| KR20250044679A (ko) | 2022-07-08 | 2025-04-01 | 아스트라제네카 아베 | 암 치료를 위한 hgf-수용체 억제제와 병용의 상피 성장 인자 수용체 티로신 키나아제 억제제 |
| US20260049059A1 (en) | 2022-11-25 | 2026-02-19 | Synthon B.V. | A process for preparation of cabozantinib or tivozanib |
| CN120239695A (zh) * | 2022-12-01 | 2025-07-01 | 江苏奥赛康药业有限公司 | 一种制备卡博替尼及其中间体的方法 |
| WO2024163400A1 (en) * | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
| IL316197A (en) * | 2023-10-17 | 2025-05-01 | Great Novel Therapeutics Biotech & Medicals Corp | Tyrosine kinase inhibitors and their uses |
| CN117843713A (zh) * | 2023-12-18 | 2024-04-09 | 上海亲合力生物医药科技股份有限公司 | 基于肿瘤微环境激活的激酶抑制剂、组合物及应用 |
| WO2025253311A1 (en) | 2024-06-04 | 2025-12-11 | Hetero Labs Limited | 1,2-dicarboxamide compounds as kinase inhibitors |
| WO2026074526A1 (en) | 2024-10-04 | 2026-04-09 | Hetero Labs Limited | 1,2-dicarboxamide compounds as kinase inhibitors |
Family Cites Families (170)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US506181A (en) | 1893-10-03 | Folding crate | ||
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| US5123951A (en) * | 1986-03-31 | 1992-06-23 | Rhone-Poulenc Nederland B.V. | Synergistic plant growth regulator compositions |
| JPS646261A (en) * | 1987-03-31 | 1989-01-10 | Nisshin Flour Milling Co | 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
| US5238951A (en) | 1991-02-01 | 1993-08-24 | E. R. Squibb & Sons, Inc. | Heterocyclic amido prostaglandin analogs |
| DE4114733A1 (de) * | 1991-05-06 | 1992-11-12 | Huels Chemische Werke Ag | Verfahren zur herstellung von substituierten malonesteraniliden und malonsaeure-monoaniliden |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (https=) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222545A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| TR199701547T1 (xx) | 1995-06-07 | 1998-03-21 | Smithkline Beecham Biologicals S.A. | Polisakarit antijen protein e�leni�i i�eren a��. |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| EP0860433B1 (en) | 1995-11-07 | 2002-07-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| NZ325248A (en) | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| AU2103097A (en) | 1996-03-15 | 1997-10-10 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| EP0882717B1 (en) | 1996-10-01 | 2010-09-08 | Kyowa Hakko Kirin Co., Ltd. | Nitrogenous heterocyclic compounds |
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| WO1998047873A1 (en) | 1997-04-18 | 1998-10-29 | Kirin Beer Kabushiki Kaisha | Process for producing quinolone derivatives |
| DE69818248T2 (de) | 1997-04-22 | 2004-06-17 | Janssen Pharmaceutica N.V. | Chinolin- und chinazolin-derivate als crf antagonisten |
| GB9708917D0 (en) | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
| JP4194678B2 (ja) * | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| IL139641A0 (en) | 1998-05-28 | 2002-02-10 | Parker Hughes Inst | Quinazolines for treating brain tumor |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| KR20010089171A (ko) | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| JP5170486B2 (ja) | 1998-09-10 | 2013-03-27 | バイオイコール ア−ゲー | 局所適用性産物 |
| ATE255575T1 (de) | 1998-09-29 | 2003-12-15 | Wyeth Corp | Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren |
| US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| ATE232205T1 (de) | 1998-10-01 | 2003-02-15 | Astrazeneca Ab | Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird |
| US7262201B1 (en) | 1998-10-08 | 2007-08-28 | Astrazeneca Ab | Quinazoline derivatives |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| ATE356117T1 (de) * | 1999-01-22 | 2007-03-15 | Kirin Brewery | Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| EP1162974A1 (en) | 1999-03-19 | 2001-12-19 | Parker Hughes Institute | Quinazoline formulations and therapeutic use thereof |
| YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| US6126917A (en) | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
| HK1044769B (zh) | 1999-06-21 | 2005-02-25 | 贝林格尔英格海姆法玛两合公司 | 雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法 |
| CA2384291A1 (en) * | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
| CA2392554A1 (en) | 1999-11-30 | 2001-06-28 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
| AU2223201A (en) * | 1999-12-24 | 2001-07-09 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| WO2001055116A2 (en) * | 2000-01-28 | 2001-08-02 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| US6664390B2 (en) | 2000-02-02 | 2003-12-16 | Warner-Lambert Company Llc | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine |
| KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| CN1190197C (zh) | 2000-03-13 | 2005-02-23 | 惠氏控股公司 | 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途 |
| US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| EP1292591B1 (en) | 2000-06-22 | 2005-02-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| IL153246A0 (en) | 2000-06-28 | 2003-07-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| EP1174118A1 (de) | 2000-06-28 | 2002-01-23 | Cognis France S.A. | Verwendung von Inulinen und Inulinderivaten |
| FR2811658B1 (fr) | 2000-07-17 | 2004-07-02 | Cfpi Nufarm | Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides |
| JP2002030083A (ja) * | 2000-07-18 | 2002-01-29 | Kirin Brewery Co Ltd | Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩 |
| US7427689B2 (en) * | 2000-07-28 | 2008-09-23 | Georgetown University | ErbB-2 selective small molecule kinase inhibitors |
| WO2002016352A1 (en) | 2000-08-21 | 2002-02-28 | Astrazeneca Ab | Quinazoline derivatives |
| US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6653305B2 (en) | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| AU2001292137A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives |
| JP2004511479A (ja) | 2000-10-13 | 2004-04-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| AU9598601A (en) * | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| AU2002212436A1 (en) | 2000-10-25 | 2002-05-06 | Astrazeneca Ab | Quinazoline derivatives |
| EP1337513A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | 4-substituted quinolines as antitumor agents |
| US7220751B2 (en) | 2000-11-02 | 2007-05-22 | Nippon Shinyaku Co., Ltd. | Quinazoline derivatives and drugs |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
| JP4307843B2 (ja) | 2001-04-19 | 2009-08-05 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| DK1382604T3 (da) | 2001-04-27 | 2006-04-18 | Kirin Brewery | Quinolinderivater med en azolylgruppe og quinazolinderivater |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| US6734303B2 (en) | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
| DE10125432A1 (de) * | 2001-05-25 | 2002-11-28 | Bayer Ag | Substituierte Benzoylketone |
| US7132427B2 (en) | 2001-06-21 | 2006-11-07 | Ariad Pharmaceuticals, Inc. | Quinazolines and uses thereof |
| AU2002313249B2 (en) * | 2001-06-22 | 2008-08-21 | Kirin Pharma Kabushiki Kaisha | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| KR100397792B1 (ko) | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| GB0118752D0 (en) | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20030066060A1 (en) | 2001-09-28 | 2003-04-03 | Ford Richard L. | Cross profile guided optimization of program execution |
| EP1447405A4 (en) | 2001-10-17 | 2005-01-12 | Kirin Brewery | CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR |
| US7169788B2 (en) | 2001-10-30 | 2007-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| AR037438A1 (es) | 2001-11-27 | 2004-11-10 | Wyeth Corp | 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
| WO2003048159A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
| GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
| AU2002347359A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
| AP2004003058A0 (en) | 2001-12-12 | 2004-06-30 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth. |
| PL370858A1 (en) | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| WO2003055866A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| WO2003055491A1 (en) | 2001-12-24 | 2003-07-10 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| US7312212B2 (en) | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
| EP1470131A2 (en) | 2002-01-29 | 2004-10-27 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| SI1474420T1 (sl) | 2002-02-01 | 2012-06-29 | Astrazeneca Ab | Spojine kinazolina |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| US20050049267A1 (en) * | 2002-03-01 | 2005-03-03 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| DE10217689A1 (de) | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| JPWO2003093238A1 (ja) * | 2002-05-01 | 2005-09-08 | 麒麟麦酒株式会社 | マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体 |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| GB0219746D0 (en) | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
| WO2004018430A1 (ja) * | 2002-08-23 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| ATE374199T1 (de) | 2002-10-21 | 2007-10-15 | Kirin Brewery | N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form |
| EP1566379A4 (en) * | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF |
| AU2003278383B2 (en) | 2002-11-04 | 2007-06-14 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| EP1569925A1 (en) | 2002-12-13 | 2005-09-07 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| RU2005119172A (ru) | 2002-12-18 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Производные 4-анилинхиназолина для лечения патологического роста клеток |
| US7238679B2 (en) | 2002-12-23 | 2007-07-03 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
| WO2004060373A1 (ja) * | 2002-12-27 | 2004-07-22 | Santen Pharmaceutical Co., Ltd. | 滲出型加齢黄斑変性治療剤 |
| US8176532B1 (en) * | 2003-03-17 | 2012-05-08 | Sprint Communications Company L.P. | Secure access point for scada devices |
| KR100559180B1 (ko) * | 2003-05-20 | 2006-03-14 | 김민서 | 조건부 거래에 따른 전자결제 방법 및 전자결제 서버 |
| WO2005003140A1 (en) | 2003-07-02 | 2005-01-13 | Pharmacia & Upjohn Company Llc | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents |
| EP1641759B1 (en) | 2003-07-07 | 2014-03-12 | Merck Patent GmbH | Malonamide derivatives |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| JP2007518823A (ja) | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7977345B2 (en) * | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
| EP1874759A4 (en) * | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| US7594258B2 (en) * | 2005-06-27 | 2009-09-22 | Yahoo! Inc. | Access control systems and methods using visibility tokens with automatic propagation |
| US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
| JP2012504606A (ja) | 2008-10-01 | 2012-02-23 | ラディック インスティテュート フォー キャンサー リサーチ | 癌の治療方法 |
| US20130030172A1 (en) | 2008-12-04 | 2013-01-31 | Exelixis, Inc. | Methods of Preparing Quinoline Derivatives |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| CN102510855B (zh) | 2009-07-17 | 2015-11-25 | 埃克塞里艾克西斯公司 | N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011031840A1 (en) | 2009-09-09 | 2011-03-17 | Quintiles Transnational Corp. | Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
| JP5461213B2 (ja) | 2010-01-29 | 2014-04-02 | 三洋電機株式会社 | 空気調和装置の室外ユニット |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
-
2004
- 2004-09-24 EP EP10160517A patent/EP2210607B1/en not_active Expired - Lifetime
- 2004-09-24 ES ES11179942.5T patent/ES2466818T3/es not_active Expired - Lifetime
- 2004-09-24 CA CA2744997A patent/CA2744997A1/en not_active Abandoned
- 2004-09-24 SI SI200432145T patent/SI2392565T1/sl unknown
- 2004-09-24 EP EP11179941.7A patent/EP2392564B1/en not_active Expired - Lifetime
- 2004-09-24 ES ES10160517T patent/ES2371383T3/es not_active Expired - Lifetime
- 2004-09-24 DK DK11179941.7T patent/DK2392564T3/da active
- 2004-09-24 DK DK11179942.5T patent/DK2392565T3/da active
- 2004-09-24 DK DK10160517.8T patent/DK2210607T3/da active
- 2004-09-24 EP EP13151957.1A patent/EP2609919A3/en not_active Withdrawn
- 2004-09-24 ES ES11179941.7T patent/ES2436888T3/es not_active Expired - Lifetime
- 2004-09-24 SI SI200432122T patent/SI2392564T1/sl unknown
- 2004-09-24 ES ES10160518T patent/ES2369652T3/es not_active Expired - Lifetime
- 2004-09-24 AT AT10160518T patent/ATE517091T1/de active
- 2004-09-24 EP EP10160518A patent/EP2213661B1/en not_active Expired - Lifetime
- 2004-09-24 EP EP13151945.6A patent/EP2612853A1/en not_active Withdrawn
- 2004-09-24 EP EP11179942.5A patent/EP2392565B1/en not_active Expired - Lifetime
- 2004-09-24 AU AU2004275842A patent/AU2004275842B2/en not_active Ceased
- 2004-09-24 AT AT10160517T patent/ATE520403T1/de active
- 2004-09-24 PT PT10160518T patent/PT2213661E/pt unknown
- 2004-09-24 PL PL10160518T patent/PL2213661T3/pl unknown
- 2004-09-24 AT AT04789057T patent/ATE532782T1/de active
- 2004-09-24 ES ES17190013T patent/ES2925655T3/es not_active Expired - Lifetime
- 2004-09-24 PL PL11179942T patent/PL2392565T3/pl unknown
- 2004-09-24 SI SI200431746T patent/SI2213661T1/sl unknown
- 2004-09-24 JP JP2006528265A patent/JP4638436B2/ja not_active Expired - Fee Related
- 2004-09-24 EP EP17190013.7A patent/EP3329918B1/en not_active Expired - Lifetime
- 2004-09-24 PL PL10160517T patent/PL2210607T3/pl unknown
- 2004-09-24 CA CA2537812A patent/CA2537812C/en not_active Expired - Lifetime
- 2004-09-24 SI SI200431754T patent/SI2210607T1/sl unknown
- 2004-09-24 ES ES11179944.1T patent/ES2651730T3/es not_active Expired - Lifetime
- 2004-09-24 DK DK10160518.6T patent/DK2213661T3/da active
- 2004-09-24 EP EP11179944.1A patent/EP2409704B1/en not_active Expired - Lifetime
- 2004-09-24 WO PCT/US2004/031523 patent/WO2005030140A2/en not_active Ceased
- 2004-09-24 EP EP04789057A patent/EP1673085B1/en not_active Expired - Lifetime
- 2004-09-24 PT PT10160517T patent/PT2210607E/pt unknown
-
2006
- 2006-10-26 US US11/586,751 patent/US9174947B2/en active Active
-
2007
- 2007-05-24 US US11/753,503 patent/US8476298B2/en not_active Expired - Fee Related
- 2007-05-24 US US11/753,462 patent/US8178532B2/en active Active
- 2007-05-24 US US11/753,514 patent/US8067436B2/en active Active
-
2009
- 2009-02-26 US US12/393,806 patent/US7579473B2/en active Active
-
2010
- 2010-07-12 JP JP2010158334A patent/JP5325172B2/ja not_active Expired - Lifetime
- 2010-07-12 JP JP2010158336A patent/JP5185332B2/ja not_active Expired - Fee Related
- 2010-07-12 JP JP2010158335A patent/JP5185331B2/ja not_active Expired - Lifetime
- 2010-07-12 JP JP2010158337A patent/JP5325173B2/ja not_active Expired - Fee Related
- 2010-07-27 AU AU2010204459A patent/AU2010204459B2/en not_active Ceased
- 2010-07-27 AU AU2010204461A patent/AU2010204461B2/en active Active
- 2010-10-25 US US12/911,442 patent/US20110077233A1/en not_active Abandoned
- 2010-11-16 JP JP2010256317A patent/JP2011042686A/ja not_active Withdrawn
-
2011
- 2011-09-30 US US13/249,815 patent/US8497284B2/en not_active Expired - Fee Related
- 2011-10-05 HR HR20110707T patent/HRP20110707T1/hr unknown
- 2011-10-19 CY CY20111100990T patent/CY1111956T1/el unknown
- 2011-11-02 HR HR20110810T patent/HRP20110810T1/hr unknown
- 2011-11-14 CY CY20111101096T patent/CY1112056T1/el unknown
-
2012
- 2012-03-22 US US13/427,093 patent/US20120184523A1/en not_active Abandoned
-
2013
- 2013-05-07 US US13/888,592 patent/US20140155378A9/en not_active Abandoned
- 2013-06-27 US US13/928,977 patent/US20140155396A1/en not_active Abandoned
- 2013-12-26 JP JP2013268453A patent/JP2014074059A/ja not_active Ceased
- 2013-12-26 JP JP2013268454A patent/JP5694501B2/ja not_active Expired - Lifetime
- 2013-12-26 JP JP2013268455A patent/JP2014055191A/ja active Pending
-
2014
- 2014-01-07 HR HRP20140012TT patent/HRP20140012T1/hr unknown
- 2014-06-13 HR HRP20140563TT patent/HRP20140563T1/hr unknown
- 2014-07-25 LU LU92508C patent/LU92508I2/xx unknown
- 2014-07-31 NL NL300678C patent/NL300678I2/nl unknown
- 2014-09-03 CY CY2014037C patent/CY2014037I2/el unknown
- 2014-09-10 BE BE2014C055C patent/BE2014C055I2/fr unknown
- 2014-09-12 FR FR14C0067C patent/FR14C0067I2/fr active Active
- 2014-09-16 HU HUS1400052C patent/HUS1400052I1/hu unknown
-
2015
- 2015-04-22 JP JP2015087327A patent/JP2015131859A/ja not_active Withdrawn
- 2015-09-08 US US14/847,801 patent/US20150376133A1/en not_active Abandoned
-
2016
- 2016-03-10 US US15/066,872 patent/US20160185725A1/en not_active Abandoned
-
2017
- 2017-06-23 JP JP2017123131A patent/JP2017160270A/ja not_active Withdrawn
- 2017-08-28 US US15/688,310 patent/US11124482B2/en not_active Expired - Fee Related
-
2019
- 2019-01-10 JP JP2019002497A patent/JP2019070015A/ja not_active Withdrawn
-
2020
- 2020-07-06 US US16/921,542 patent/US20200331860A1/en not_active Abandoned
- 2020-12-18 JP JP2020209919A patent/JP2021050233A/ja not_active Withdrawn
-
2023
- 2023-11-29 JP JP2023201921A patent/JP2024023447A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010265302A5 (https=) | ||
| JP2019094345A5 (https=) | ||
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| JP2022506887A5 (https=) | ||
| RU2009102535A (ru) | Производные карбамидов тропана, их получение и их применение в терапии | |
| JP2008528467A5 (https=) | ||
| JP2017519781A5 (https=) | ||
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2009513703A5 (https=) | ||
| JP2017502940A5 (https=) | ||
| JP2013503903A5 (https=) | ||
| CA2932831A1 (en) | Substituted nicotinamide derivatives as kinase inhibitors | |
| JP2010539110A5 (https=) | ||
| EP2782577A2 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2007534695A5 (https=) | ||
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| EP4323349A1 (en) | Isoindolinone amide compounds useful to treat diseases associated with gspt1 | |
| JP2020500182A5 (https=) | ||
| JP2018516994A5 (https=) | ||
| CA2943022C (en) | Benzo[g]pyrido[2,1-b] quinazoline carboxamide compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| RU2011136821A (ru) | Дигидрохинолиноновые производные | |
| JP2015531764A5 (https=) | ||
| JP2010506919A5 (https=) | ||
| JP2011510972A5 (https=) |